EGFR and non-small cell lung carcinoma: The above experimental results show that although NSCLC patients with abnormal EGFR prefer TKI therapy compared to those with normal EGFR, clinical EGFR-TKI therapy does not have a significant advantage over first-line chemotherapeutic agents in NSCLC patients with abnormal EGFR based on the available data.